Pharmaceuticals
Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on Lung Cancer
* Data analysis to explore demonstrated anti-tumor activity of BBT-176, a fourth generation EGFR TKI, in advanced non-small cell lung cancer SEONGNAM, South Korea , May 10 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on deve...
2022-05-10 21:00
2296
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated tri...
2022-05-10 20:50
2488
Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the Company w...
2022-05-10 16:54
3115
AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
SHANGHAI, May 9, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, held a DEXTENZA Launch and Advisory Board Meeting recently inMacau, f...
2022-05-10 09:00
1949
iNtRON Biotechnology, Inc., Launches New Website
It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- The parent company of iNtODEWORLD, Inc., iNtRON Biotechnology, Inc., ("iNtRON" or "Company") is ...
2022-05-09 21:00
2454
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Fin...
2022-05-09 08:04
2160
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment o...
2022-05-06 08:00
2493
Daewoong Pharmaceutical announced first-quarter 2022 results
- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the...
2022-05-05 21:00
2436
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign...
2022-05-05 20:00
2012
111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act
SHANGHAI, May 5, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that onMay 4th, 2022, the Securities and Exchange Commission (the "SEC") provisionally listed the Company as a "Commission-Identified ...
2022-05-05 17:18
2343
Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma
SUZHOU, China, May 4, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing inthe United States of its multi-regional pha...
2022-05-04 20:36
2765
United Imaging Flips the Script on its Events Program for 2022, Reveals Expanded Sales Force and U.S. Growth
Its new AE University also trains new salespeople on the company's unique take on medical imaging purchasing. HOUSTON, May 3, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, said that it has enhanced its U.S. domestic events progr...
2022-05-03 23:22
2198
Inmagene Receives FDA's IND Clearance for OX40 Antagonist
SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I clinical development. Inmagene is de...
2022-05-01 06:00
4213
IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
SHENZHEN, China, April 29, 2022 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination...
2022-04-29 20:00
1451
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
- Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO - Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and GAITHE...
2022-04-29 04:01
2231
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting
TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838
2022-04-28 20:00
1981
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving...
2022-04-28 08:18
1967
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, April 27, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2022-04-27 20:30
1931
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healt...
2022-04-27 19:40
2165
Samsung Biologics Reports First Quarter 2022 Financial Results
* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21. * Stable business operations and utilization rates across Plants 1, 2, and 3. * Proactive investments into long-term growth, capacity, and su...
2022-04-27 14:42
2239
Week's Top Stories
Most Reposted
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 309 media titles]
2026-03-04 12:35
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 290 media titles]
2026-03-02 09:00
Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 290 media titles]
2026-03-03 15:49
COL and NASDAQ-Listed BeLive Holdings Unveil World's First "Microdrama in a Box" in Headline Hong Kong FILMART 2026 Launch
[Picked up by 286 media titles]
2026-03-05 17:14
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
9734
